MA37849A1 - Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux - Google Patents

Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux

Info

Publication number
MA37849A1
MA37849A1 MA37849A MA37849A MA37849A1 MA 37849 A1 MA37849 A1 MA 37849A1 MA 37849 A MA37849 A MA 37849A MA 37849 A MA37849 A MA 37849A MA 37849 A1 MA37849 A1 MA 37849A1
Authority
MA
Morocco
Prior art keywords
disease
parkinson
syndrome
treating fragile
diazepinone derivatives
Prior art date
Application number
MA37849A
Other languages
English (en)
Inventor
Dirk Behnke
David Carcache
Peter Ertl
Manuel Koller
David Orain
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47045285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37849(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37849A1 publication Critical patent/MA37849A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i) ou un sel de celui-ci, pour lequel les substituants sont tels que définis dans la description ; sa préparation, son utilisation en tant que médicament et des médicaments le comprenant.
MA37849A 2012-08-23 2013-08-21 Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux MA37849A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1215033.0A GB201215033D0 (en) 2012-08-23 2012-08-23 Diazepinone derivatives
PCT/IB2013/056782 WO2014030128A1 (fr) 2012-08-23 2013-08-21 Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux

Publications (1)

Publication Number Publication Date
MA37849A1 true MA37849A1 (fr) 2017-09-29

Family

ID=47045285

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37849A MA37849A1 (fr) 2012-08-23 2013-08-21 Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux

Country Status (43)

Country Link
US (4) US8853203B2 (fr)
EP (1) EP2888259B1 (fr)
JP (2) JP6169699B2 (fr)
KR (1) KR102104149B1 (fr)
CN (1) CN104520298B (fr)
AP (1) AP2014008140A0 (fr)
AR (1) AR092212A1 (fr)
AU (1) AU2013307239B2 (fr)
BR (1) BR112015003281A8 (fr)
CA (1) CA2878564C (fr)
CL (1) CL2015000416A1 (fr)
CR (1) CR20150092A (fr)
CU (1) CU20150016A7 (fr)
CY (1) CY1120728T1 (fr)
DK (1) DK2888259T3 (fr)
EA (1) EA029493B1 (fr)
ES (1) ES2672737T3 (fr)
GB (1) GB201215033D0 (fr)
GT (1) GT201500039A (fr)
HR (1) HRP20180850T1 (fr)
HU (1) HUE037971T2 (fr)
IL (1) IL237062A (fr)
JO (1) JOP20130250B1 (fr)
LT (1) LT2888259T (fr)
MA (1) MA37849A1 (fr)
MX (1) MX365253B (fr)
MY (1) MY170103A (fr)
NO (1) NO2888259T3 (fr)
NZ (1) NZ703628A (fr)
PE (1) PE20150401A1 (fr)
PH (1) PH12015500373A1 (fr)
PL (1) PL2888259T3 (fr)
PT (1) PT2888259T (fr)
RS (1) RS57231B1 (fr)
SG (2) SG11201500068QA (fr)
SI (1) SI2888259T1 (fr)
TN (1) TN2014000528A1 (fr)
TR (1) TR201807174T4 (fr)
TW (1) TWI616444B (fr)
UA (1) UA114326C2 (fr)
UY (1) UY34986A (fr)
WO (1) WO2014030128A1 (fr)
ZA (1) ZA201409345B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201215033D0 (en) 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
KR20210120011A (ko) * 2019-01-29 2021-10-06 노파르티스 아게 오피오이드 진통제 내약성을 치료하기 위한 mglur5 길항제의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853851A (en) * 1972-01-26 1974-12-10 Ciba Geigy Corp Diazepinoisoquinolines
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
AU2004226450A1 (en) * 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
CU20090172A7 (es) 2009-10-09 2011-10-05 Ct De Investigación Y Desarrollo De Medicamentos Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
CA2784830C (fr) * 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Composes pour le traitement des troubles medies par le recepteur metabotropique 5 du glutamate, et leurs methodes d'utilisation
ES2693152T3 (es) 2011-05-10 2018-12-07 Kyowa Hakko Kirin Co., Ltd. Compuesto de pirimido-diazepinona
GB201215033D0 (en) * 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives

Also Published As

Publication number Publication date
CL2015000416A1 (es) 2015-04-24
CA2878564A1 (fr) 2014-02-27
MY170103A (en) 2019-07-05
NO2888259T3 (fr) 2018-08-04
GT201500039A (es) 2018-11-27
MX365253B (es) 2019-05-28
EA029493B1 (ru) 2018-04-30
CN104520298B (zh) 2016-10-19
UY34986A (es) 2014-03-31
WO2014030128A1 (fr) 2014-02-27
HUE037971T2 (hu) 2018-10-29
US8853203B2 (en) 2014-10-07
EA201590415A1 (ru) 2015-06-30
AU2013307239B2 (en) 2015-12-24
CY1120728T1 (el) 2019-12-11
TWI616444B (zh) 2018-03-01
GB201215033D0 (en) 2012-10-10
MX2015002367A (es) 2015-06-03
NZ703628A (en) 2018-05-25
ES2672737T3 (es) 2018-06-15
JOP20130250B1 (ar) 2021-08-17
TW201412736A (zh) 2014-04-01
SG10201701333WA (en) 2017-04-27
US20140057902A1 (en) 2014-02-27
TR201807174T4 (tr) 2018-06-21
RS57231B1 (sr) 2018-07-31
DK2888259T3 (en) 2018-06-14
CN104520298A (zh) 2015-04-15
TN2014000528A1 (en) 2016-03-30
EP2888259A1 (fr) 2015-07-01
SI2888259T1 (en) 2018-07-31
JP2017226661A (ja) 2017-12-28
PL2888259T3 (pl) 2018-08-31
PE20150401A1 (es) 2015-04-16
AU2013307239A1 (en) 2015-01-29
KR20150044897A (ko) 2015-04-27
US9650377B2 (en) 2017-05-16
BR112015003281A8 (pt) 2018-01-16
KR102104149B1 (ko) 2020-04-24
CR20150092A (es) 2015-05-04
US9284331B2 (en) 2016-03-15
IL237062A (en) 2016-11-30
US20140357625A1 (en) 2014-12-04
UA114326C2 (uk) 2017-05-25
US20170305903A1 (en) 2017-10-26
HK1206008A1 (en) 2015-12-31
LT2888259T (lt) 2018-06-11
US20160159795A1 (en) 2016-06-09
PH12015500373B1 (en) 2015-04-20
AP2014008140A0 (en) 2014-12-31
CA2878564C (fr) 2021-08-03
EP2888259B1 (fr) 2018-03-07
HRP20180850T1 (hr) 2018-06-29
ZA201409345B (en) 2015-12-23
CU20150016A7 (es) 2015-07-30
BR112015003281A2 (pt) 2017-07-04
JP2015526461A (ja) 2015-09-10
PH12015500373A1 (en) 2015-04-20
AR092212A1 (es) 2015-04-08
JP6169699B2 (ja) 2017-07-26
PT2888259T (pt) 2018-06-06
SG11201500068QA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA47217B1 (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA40523B1 (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EP2889032A4 (fr) Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA38358A1 (fr) Formulations de composés organiques
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA38307A1 (fr) 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
MA38250B1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer